

CENTENE PHARMACY AND THERAPEUTICS
THERAPEUTIC CLASS MATRIX
GPI Code 32: Antianginals
1Q18 January - February

Review Time Frame: November 2016 – October 2017

Background:

Antianginal agents are used in the management of angina pectoris. With the exception of ranolazine, a piperazine derivative, there are three classes of drugs indicated for the management of angina pectoris. These three classes of antianginals are:

- Beta-blockers - relieve anginal symptoms by reducing both heart rate and contractility;
- Calcium channel blockers - improve anginal symptomatology by causing coronary and peripheral vasodilation and reducing contractility;
- Nitrates - cause a transient increase in heart rate and myocardial contractility that normally would increase myocardial oxygen consumption, resulting in a net decrease in myocardial oxygen demand and amelioration of the pain of angina pectoris.

This review addresses antianginals other than beta blockers and calcium channel blockers as these agents are reviewed in therapeutic class review matrix.

New Drugs:

None identified.

Discontinued Drugs:

None identified.

FDA Safety Warnings:

None identified.

REVIEW RECOMMENDATION

There is no existing clinical guidance for this drug class.

References:

1. Amsterdam EA, Wenger NK, Brindis RG, et al. Guideline for the management of patients with non-ST-elevation acute coronary syndromes: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2014;130(25):2354.
2. Fihn SD, Blankenship JC, Alexander KP, et al. Focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. *J Am Coll Cardiol* 2014; 64:1929.
3. Fihn SD, Gardin JM, Abrams J, et al. Guideline for the diagnosis and management of patients with stable ischemic heart disease: A report of the American College of Cardiology

CENTENE PHARMACY AND THERAPEUTICS
THERAPEUTIC CLASS MATRIX
GPI Code 32: Antianginals
1Q18 January - February

Review Time Frame: November 2016 – October 2017

Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. American College of Cardiology Foundation/American Heart Association Task Force. *Circulation*. 2012; 126(25):e354. Epub 2012 Nov 19.

4. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2017. Available at <http://www.clinicalpharmacology-ip.com/>. Accessed November 2017.
5. U.S. Food and Drug Administration. WWW.FDA.GOV.